液体活检
胰腺癌
胰腺上皮内瘤变
医学
克拉斯
GNAS复合轨迹
病理
发育不良
CDKN2A
外科肿瘤学
胰腺
活检
腺癌
胎儿游离DNA
癌症
肿瘤科
内科学
胰腺导管腺癌
结直肠癌
生物
基因
怀孕
产前诊断
胎儿
生物化学
遗传学
作者
Kenji Takahashi,Yohei Takeda,Yusuke Ono,Hajime Isomoto,Yusuke Mizukami
标识
DOI:10.1007/s00535-023-02024-4
摘要
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal cancers, and developing an efficient and reliable approach for its early-stage diagnosis is urgently needed. Precancerous lesions of PDAC, such as pancreatic intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasms (IPMN), arise through multiple steps of driver gene alterations in KRAS, TP53, CDKN2A, SMAD4, or GNAS. Hallmark mutations play a role in tumor initiation and progression, and their detection in bodily fluids is crucial for diagnosis. Recently, liquid biopsy has gained attention as an approach to complement pathological diagnosis, and in addition to mutation signatures in cell-free DNA, cell-free RNA, and extracellular vesicles have been investigated as potential diagnostic and prognostic markers. Integrating such molecular information to revise the diagnostic criteria for pancreatic cancer can enable a better understanding of the pathogenesis underlying inter-patient heterogeneity, such as sensitivity to chemotherapy and disease outcomes. This review discusses the current diagnostic approaches and clinical applications of genetic analysis in pancreatic cancer and diagnostic attempts by liquid biopsy and molecular analyses using pancreatic juice, duodenal fluid, and blood samples. Emerging knowledge in the rapidly advancing liquid biopsy field is promising for molecular profiling and diagnosing pancreatic diseases with significant diversity.
科研通智能强力驱动
Strongly Powered by AbleSci AI